Scynexis SCYX
NASDAQ SCYX
$4.90 +0.24 (+5.15%)
As of: Sep 30, 2026 · 3:49 PM EDT

Scynexis (SCYX) Interest Coverage Ratio (2016 - 2025)

Updated

Scynexis' Interest Coverage Ratio was -92.91 in FY2025, compared with -44.83 in FY2024.

Analysis

Scynexis (SCYX) Interest Coverage Ratio (2016 - 2025) Analysis & Trends

From FY2014 onward, Scynexis has reported Interest Coverage Ratio for 12 years.

  • The FY2025 figure marks the lowest annual Interest Coverage Ratio since FY2015.
  • Per Business Quant data, Interest Coverage Ratio in earlier years was -44.83 in FY2024, 23.22 in FY2023, -16.50 in FY2022 and -22.87 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 25.41
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn -
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 10.28
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 7.27
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 5.22
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -42.08
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Scynexis 46.37 Mn -24.73 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 -49.77
Dec 31, 2024 -38.17
Sep 30, 2024 -48.45
Jun 30, 2024 -46.89
Mar 31, 2024 -46.38
Dec 31, 2023 -103.90
Sep 30, 2023 -47.63
Jun 30, 2023 93.29
Mar 31, 2023 -7.38
Dec 31, 2022 -14.70
Sep 30, 2022 -15.81
Jun 30, 2022 -17.66
Mar 31, 2022 -18.64
Dec 31, 2021 -22.71
Sep 30, 2021 -19.08
Jun 30, 2021 -39.34
Mar 31, 2021 -7.45
Dec 31, 2020 -47.63
Sep 30, 2020 -34.88
Jun 30, 2020 -37.07
API Access

Scynexis Interest Coverage Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-coverage-ratio&ticker=SCYX&period=max&api_key=YOUR_API_KEY